Literature DB >> 30326143

Intravenous immunoglobulin G treatment increases live birth rate in women with recurrent miscarriage and modulates regulatory and exhausted regulatory T cells frequency and function.

Sara Jafarzadeh1,2, Majid Ahmadi1,2, Sanam Dolati3,4, Leili Aghebati-Maleki4,5, Shadi Eghbal-Fard4, Amin Kamrani4, Behboud Behrad6, Leila Roshangar1, Farhad Jadidi-Niaragh4, Bahman Yousefi7, Mahdi Mehdipour1,6, Laya Farzadi6, Mehdi Yousefi2,4.   

Abstract

Exhausted T cells and regulatory T (Treg) cells have been recently proposed to be new risk factors for recurrent miscarriage (RM). Intravenous immunoglobulin G (IVIG) treatment reported to modulate various immune cells. In this study, the effects of IVIG on the frequency and function of exhausted T cells, exhausted Tregs, and Treg cells, as well as pregnancy outcome in women with unexplained RM (URM), were investigated. Ninety-four pregnant women with RM were enrolled. At the time of positive pregnancy, blood samples were drawn. Forty-four patients with URM were included as IVIG receiving treated group and received 400 mg/kg of IVIG and the rest fifty patients were considered as a control group and received no IVIG administration. IVIG was given intravenously every 4 weeks during 32 weeks of gestation. Blood samples of patients were collected after the latest administration. Exhausted T cells, exhausted Tregs, and Treg cells were evaluated pre- and posttreatment in both groups. IVIG induced a significant decrease in the frequency of exhausted Tregs population and function as well as a significant increase in Treg cells population, however, IVIG failed to affect population and the function of exhausted T cells. Pregnancy outcome was successful in IVIG treated women (86.3%) and were significantly different (P = 0.0006) in compared with the untreated URM subjects (42%). Therefore, employing of IVIG increases Treg cells and diminishes exhausted Tregs responses in RM patients with cellular immune anomalies throughout the pregnancy. Immunemodulatory effects of IVIG are probably associated with successful pregnancy outcome.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  exhausted T cell; immunoglobulin; intravenous immunoglobulin G (IVIG); recurrent miscarriage (RM); regulatory T-cell (Treg)

Mesh:

Substances:

Year:  2018        PMID: 30326143     DOI: 10.1002/jcb.27821

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  6 in total

Review 1.  Female Unexplained Infertility: A Disease with Imbalanced Adaptive Immunity.

Authors:  Motahareh Ehsani; Mousa Mohammadnia-Afrouzi; Mohammad Mirzakhani; Sedighe Esmaeilzadeh; Mehdi Shahbazi
Journal:  J Hum Reprod Sci       Date:  2019-12-17

Review 2.  Regulation of the innate immune cells during pregnancy: An immune checkpoint perspective.

Authors:  Wen-Xuan Li; Xiang-Hong Xu; Li-Ping Jin
Journal:  J Cell Mol Med       Date:  2021-10-28       Impact factor: 5.310

Review 3.  High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects.

Authors:  Xiaosheng Liu; Wei Cao; Taisheng Li
Journal:  Front Immunol       Date:  2020-07-14       Impact factor: 7.561

Review 4.  Role of Regulatory T Cells in Regulating Fetal-Maternal Immune Tolerance in Healthy Pregnancies and Reproductive Diseases.

Authors:  Ning Huang; Hongbin Chi; Jie Qiao
Journal:  Front Immunol       Date:  2020-06-26       Impact factor: 7.561

Review 5.  The exploration of Hashimoto's Thyroiditis related miscarriage for better treatment modalities.

Authors:  Yu Min; Xing Wang; Hang Chen; Guobing Yin
Journal:  Int J Med Sci       Date:  2020-08-29       Impact factor: 3.738

Review 6.  Intravenous immunoglobulins improve live birth rate among women with underlying immune conditions and recurrent pregnancy loss: a systematic review and meta-analysis.

Authors:  Denise H J Habets; Kim Pelzner; Lotte Wieten; Marc E A Spaanderman; Eduardo Villamor; Salwan Al-Nasiry
Journal:  Allergy Asthma Clin Immunol       Date:  2022-03-11       Impact factor: 3.406

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.